Patents Assigned to Genzyme Corporation
  • Patent number: 10035829
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: July 31, 2018
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • Publication number: 20180208650
    Abstract: Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.
    Type: Application
    Filed: January 19, 2018
    Publication date: July 26, 2018
    Applicant: Genzyme Corporation
    Inventors: Huawei Qiu, Sunghae Park, James Stefano
  • Patent number: 10028731
    Abstract: Described is a barrier application device comprising a handle, an introducer assembly slidably and rotatably coupled to the handle, a beam assembly coupled to a distal end of the handle, and a flag coupled to the beam assembly. A method of using a barrier application device comprises providing a device comprising a handle, an introducer assembly slidably and rotatably coupled to the handle, a beam assembly coupled to a distal end of the handle, and a flag coupled to the beam assembly, and placing a barrier on the flag, sliding the introducer assembly along the handle from a retracted position to an extended position at least partially covering the beam assembly, and rotating the handle relative to the introducer assembly until the flag and the barrier are wound around the beam assembly.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: July 24, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Jeffrey Kapec, Kazuna Tanaka, Yukiko Naoi, Joseph Jeffrey Kablik
  • Patent number: 10022428
    Abstract: The present disclosure provides methods of screening, diagnosing, monitoring and/or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and/or treatment of an ASM disorder, for example using enzyme replacement therapy.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: July 17, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Wei-Lien Chuang, Gerald F. Cox, X. Kate Zhang
  • Patent number: 10017746
    Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: July 10, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Pauline McLean Quigley Sheldon, Peter S. Gagnon, Gina Nichols, Barbara A. Thorne
  • Patent number: 10017523
    Abstract: The invention features compounds of Formula (I), Formula (I)-A and Formula (I)-B as disclosed herein, as well as methods of synthesis, therapy, diagnostics, and assays.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: July 10, 2018
    Assignee: Genzyme Corporation
    Inventors: Paul Mason, Kara Carter, Alexandra Joseph, Yiding Hu, Jill Gregory, Zhong Zhao, Christopher Yee, Mohamud Mohamud, Yibin Xiang, Sanjay Danthi, Yinyin Huang, Andrew Papoulis
  • Patent number: 10017573
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 10, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • Publication number: 20180180525
    Abstract: Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation. Recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenoviral particles, recombinant lentiviral particles and recombinant herpes simplex virus particles. Variant species of recombinant viral particles including empty capsids and recombinant viral particles with variant genomes (e.g., truncated genomes, aggregates, recombinants) can be identified and quantitated. The methods can be used to characterize preparations of recombinant viral particles regardless of the sequence of the recombinant viral genome or the serotype of the recombinant viral capsid.
    Type: Application
    Filed: January 19, 2016
    Publication date: June 28, 2018
    Applicants: Genzyme Corporation, Genzyme Corporation
    Inventors: Catherine R. O'RIORDAN, Brenda BURNHAM
  • Publication number: 20180155417
    Abstract: Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Ig like domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.
    Type: Application
    Filed: October 17, 2017
    Publication date: June 7, 2018
    Applicant: Genzyme Corporation
    Inventors: Abraham Scaria, Peter Pechan, Samuel Wadsworth
  • Patent number: 9968369
    Abstract: One aspect of the present invention relates to a method of using peristalsis to force a polymer plug through a mammalian lumen, thereby removing any calculi and/or calculi fragments present in the lumen. In one embodiment, the method is used as an alternative to conventional lithotripsy. In another embodiment, the method is used in conjunction with lithotripsy, thereby removing the small calculi fragments that result from such procedures.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: May 15, 2018
    Assignee: Genzyme Corporation
    Inventors: W. Scott McDougal, Dianne E. Sacco, Alexander Schwarz, Jean-Marie Vogel
  • Publication number: 20180118716
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: October 27, 2017
    Publication date: May 3, 2018
    Applicant: Genzyme Corporation
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Publication number: 20180099946
    Abstract: The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3 (wherein R3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4 alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkenylR3 (wherein R3 is as defined hereinbefore); 3) C2-5alkynylR3 (wherein R3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
    Type: Application
    Filed: June 19, 2017
    Publication date: April 12, 2018
    Applicant: Genzyme Corporation
    Inventors: Andrew Peter Thomas, Elaine Sophie Elizabeth Stokes, Laurent Francois Andre Hennequin
  • Patent number: 9931358
    Abstract: The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: April 3, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Joseph Tyler, John S. Petersen
  • Patent number: 9920318
    Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: March 20, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Scott D. Estes, Weiqun Zhang
  • Publication number: 20180065957
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
    Type: Application
    Filed: April 18, 2017
    Publication date: March 8, 2018
    Applicant: Genzyme Corporation
    Inventors: Elyse BOURQUE, Mario A. CABRERA-SALAZAR, Cassandra CELATKA, Seng H. CHENG, Bradford Hirth, Andrew GOOD, Katherine JANCSICS, John MARSHALL, Markus Metz, Ronald K. SCHEULE, Renato SKERLJ, Yibin XIANG, Zhong ZHAO, John LEONARD, Thomas NATOLI, Elina MAKINO, Herve HUSSON, Oxana BESKROVNAYA
  • Patent number: 9909101
    Abstract: Provided herein are methods of perfusion culturing an adherent mammalian cell using a shake flask and a plurality of microcarriers, and various methods that utilize these culturing methods.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: March 6, 2018
    Assignee: Genzyme Corporation
    Inventors: Jianguo Yang, Yang Yang, Jennifer Tengtrakool, Weichang Zhou
  • Publication number: 20180055916
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Application
    Filed: April 12, 2017
    Publication date: March 1, 2018
    Applicants: Icahn School of Medicine at Mount Sinai, Genzyme Corporation
    Inventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
  • Publication number: 20180055939
    Abstract: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.
    Type: Application
    Filed: March 28, 2017
    Publication date: March 1, 2018
    Applicant: Genzyme Corporation
    Inventors: Hema S. Sista, Yero J. Espinoza
  • Publication number: 20180051054
    Abstract: Provided herein are methods of processing a fluid that include the use of one or both of a circuit system including a tangential flow filtration (TFF) unit and a circuit system including a tangential flow virus filtration (TFVF) unit. Also provided are integrated and continuous processes for manufacturing a therapeutic protein drug substance that include a step of processing a fluid including the recombinant therapeutic protein using any of the methods provided herein.
    Type: Application
    Filed: August 15, 2017
    Publication date: February 22, 2018
    Applicant: Genzyme Corporation
    Inventors: Tarl Vetter, Michael Coolbaugh, Veena Warikoo, Konstantin Konstantinov
  • Patent number: 9895315
    Abstract: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: February 20, 2018
    Assignee: Genzyme Corporation
    Inventors: Hitesh R. Bhagat, Jeffrey M. Goldberg, Abizer I. Harianawala, Louis Brenner